Genyrel Therapeutics
Explore the latest insights on Genyrel Therapeutics and its impact on China’s pharmaceutical industry. Fineline Info & Tech delivers reliable data, news, and intelligence to help you navigate the complexities of Genyrel Therapeutics’ developments with precision and clarity. Stay informed and enhance your decision-making at flcube.com.
Betta Pharmaceuticals Licenses Next‑Generation ALK Inhibitor Ensartinib to Mankind Pharma for India – Upfront, Milestones and Tiered Royalties in Exclusive Territory Deal
Betta Pharmaceuticals (SHE: 300558) announced that it has entered into a licensing agreement with leading Indian pharmaceutical company Mankind Pharma (BOM: 543904; NSE: MANKIND), granting Mankind exclusive rights to ensartinib…
Empowering Chinese Pharma’s Global Expansion
Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
